BioLineRx to Present at the 2012 Fifth Annual LD MICRO Conference in Los
Angeles on December 5th
JERUSALEM -- November 30, 2012
BioLineRx Ltd. (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development
company, today announced that its management team will be presenting at the
2012 Fifth Annual LD MICRO Conference at the Luxe Sunset Bel Air Hotel in Los
The Chief Executive Officer of BioLineRx, Dr. Kinneret Savitsky, and the
Company’s Chief Financial and Operating Officer, Mr. Philip Serlin, are
scheduled to present at 11:30 a.m. PT on Wednesday, December 5^th. The
presentation will be broadcast over the Internet as a "live" listen only
Webcast. To listen, please go to: webcast link. For those unable to listen to
the live presentation, an archive of the event will also be available for 90
Investors attending the conference that wish to meet with Dr. Savitsky or Mr.
Serlin for a one-on-one meeting should notify their LD Micro contact.
BioLineRx is a publicly-traded biopharmaceutical development company.
BioLineRx is dedicated to building a portfolio of products for unmet medical
needs or with advantages over currently available therapies. BioLineRx’s
current portfolio consists of six clinical stage candidates: BL-1020 for
schizophrenia is currently undergoing a Phase II/III study; BL-1040, for
prevention of pathological cardiac remodeling following a myocardial
infarction, which has been out-licensed to Ikaria Inc., is currently
undergoing a pivotal CE-Mark registration trial; BL-5010 for non-surgical
removal of skin lesions has completed a Phase I/II study; BL-1021 for
neuropathic pain is in Phase I development, BL-7040 for treating inflammatory
bowel disease (IBD) is currently undergoing a Phase II trial, and BL-8040 for
treating acute myeloid leukemia (AML) and other hematological cancers has
completed Phase I. In addition, BioLineRx has eight products in various
pre-clinical development stages for a variety of indications, including
central nervous system diseases, infectious diseases, cardiovascular and
BioLineRx’s business model is based on acquiring molecules mainly from
biotechnological incubators and academic institutions. The Company performs
feasibility assessment studies and development through pre-clinical and
clinical stages, with partial funding from the Israeli Government’s Office of
the Chief Scientist (OCS). The final stage includes partnering with medium and
large pharmaceutical companies for advanced clinical development (Phase 3) and
For more information on BioLineRx, please visit www.biolinerx.com.
KCSA Strategic Communications
Garth Russell / Todd Fromer
1 212-896-1250 / 1 212-896-1250
firstname.lastname@example.org / email@example.com
Press spacebar to pause and continue. Press esc to stop.